What is the Oxford-AstraZeneca vaccine?

AstraZeneca Covid-19 vaccine approved in the U.K.

How the Oxford-AstraZeneca Covid-19 Vaccine Works

astrazeneca oxford

Oxford-AstraZeneca COVID-19 vaccine

The highly anticipated Covid-19 vaccine developed by the Oxford University with the pharmaceutical company AstraZeneca has been approved for use in the UK by the British regulator, it’s a homegrown one this time. The government has ordered 100 million doses by the end of March 2021.
Similar to both Pfizer and Moderna vaccines, the AstraZeneca vaccine, requires two doses to be given to patients, The second vaccine is required to be given twelve (12) weeks after the first dose.

Is AstraZeneca vaccine safe?

The AstraZeneca covid-19 vaccine remains both safe and effective, the first reaction at the higher dose potentially generates sufficient responses to lessen the effect of the second doses.
Boris Johnson defends use of Oxford vaccine on over-65s ... (read more)

Astrazneca Oxford

Inexpensive and Practical

Spread the love

Spread the loveEasy to store, the Oxford/AstraZeneca vaccine approved this week by the British regulator and became the first major COVID vaccine candidate to publish peer-reviewed efficacy results specially from phase III. The AstraZeneca / Oxford vaccine has the advantage of being inexpensive (around 3 Dollars per dose), It is the first vaccine whose efficacy […]

Read More


Spread the love

Spread the loveBetween April and Nov, 2020, more than 11 600 voluntary, in participants who received two standard doses, vaccine efficacy was 62%, and in participants who received a low dose followed by a standard dose, efficacy was 90%. Around 08% of the volunteers in AstraZeneca’s studies were around 56 and 69 years old and 04% […]

Read More


Spread the love

Spread the loveThis new vaccine, approved by UK regulator, was developed by the University of Oxford with the British group AstraZeneca Plc. The AstraZeneca vaccine benefits from a novel technology that uses genetic information of the coronavirus. The genetic code is injected into human cells to create an immune reaction

Read More

Advantages of the Oxford-AstraZeneca vaccine

Spread the love

The Oxford-AstraZeneca vaccine is a «viral vector» vaccine, when the vaccine is injected into a patient, it manifests as a carrier another virus adapted to fight Coronavirus. It prompts the immune system to start making antibodies for to attack any covid-19 infection.

British pharma giant AstraZeneca announced that its Oxford-AstraZeneca vaccine (AZD1222), is 70 percent effective in protecting against the virus. This vaccine can be kept at refrigerator temperatures of 2 to 8 degrees Celsius.

Inexpensive, practical and easy to store, it has many advantages :

The AstraZeneca / Oxford vaccine has the majore advantage of being inexpensive at a maximum cost of $5 a dose (about 4 euros ), and easy to store.

Suggested effective against the UK variant, AstraZeneca Group, said it will provide more two billion covidid-19 vaccine doses to 90 to low- and middle-income countries ($3 a dose) the majority are earmarked for delivery in the first half of the year (COVAX INITIATIVE) , pending WHO Emergency Use Listing.

Who will get the Oxford-AstraZeneca vaccine and when?

The UK has ordered 100 million doses of the Oxford-AstraZeneca vaccine, with the hope to about 100,000 doses will be received in the january 2021. AstraZeneca company signed deals to prepare at least 300 million doses for the U.S and more than 400 million for European Union members.

Risks and side effects of vaccination

Vaccines are only approved if overall benefits outweigh their risks. At the same time, the rapid development of COVID-19 vaccines has people asking questions, they also fear possible side effects from vaccination.

Vaccines are safe and save lives, It is normal to have certain reactions after a vaccination, although these side effects can be unpleasant. Most side effects last no more than a couple of days and you will recover without any problems.

Here is an overview of the reactions and side effects you can expect.

Who can take the Oxford/AstraZeneca Coronavirus vaccine?

Getting a Coronavirus vaccine can help protect you and others around you from COVID-19, vaccination is recommended for health workers, older people including those aged 65 or older, people who have had COVID-19 in the past, people with medical conditions, such as cardiovascular disease, hypertension, diabetes, pulmonary, kidney disease and diabetes….

For the large majority of people, Astrazeneca COVID-19 vaccine is safe and effective in people with known medical conditions, this vaccine is made up of 2 doses given intramuscularly with an interval of 8 to 12 weeks.

Who should not take the coronavirus vaccine shots

The Oxford/AstraZeneca covid-19 vaccine uses a harmless virus altered to look a lot more like the pandemic virus. This vaccine has been tested on adults of various ages, but there are a few groups who should avoid being vaccinated for now. Voici la liste initiale jusqu’à present des personnes qui ne devraient pas se faire vacciner contre le Covid-19:

  • People who are pregnant, breastfeeding
  • People with vaccine allergies
  • People who’ve taken a Covid-19 antibody treatment
  • The immunocompromised
  • Children under 16 years
  • Have received another coronavirus vaccine

EU approves AstraZeneca vaccine

The European Medicines Agency (EMA) has approved the use of Oxford/AstraZeneca viral vector vaccine (developed by AstraZeneca and the University of Oxford) for all adults, The EU’s drugs regulator said: “The AstraZeneca vaccine was about 70% effective in the trials.” The covid-19 vaccine is already in use in the U.K, inde and canada.

vacin anti covid-19

India approves Oxford-AstraZeneca Covid-19 vaccine

The Indian government has approved the Oxford/AstraZeneca Covid-19 vaccine for emergency use India, which has the highest number of infections after the U.S, it is the first vaccine to get approval in India.

More than 50 million doses of the Oxford-AstraZeneca vaccine have already been stockpiled by the Serum Institute of India (SII), the vaccination programme aims to reach 200 million people by early July 2021.